15.06

1.35% 0.20

Avadel Pharmaceuticals Plc (AVDL)

Overview News Price History Option Chain Financials Why AVDL Down? Discussions Forecast

Avadel Pharmaceuticals Plc stock is traded at $15.06, with a volume of 278.68K. It is up +1.35% in the last 24 hours and up +15.05% over the past month. Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Previous Close:

$14.86

Open:

$14.83

24h Volume:

278.68K

Relative Volume:

0.30

Market Cap:

$1.43B

Revenue:

$47.56M

Net Income/Loss:

$-156.83M

P/E Ratio:

-7.2404

EPS:

-2.08

Net Cash Flow:

$-127.98M

1W Performance:

+16.56%

1M Performance:

+15.05%

6M Performance:

-19.98%

1Y Performance:

+38.42%

1-Day Range:

$14.45

$15.06

1-Week Range:

$12.69

$16.58

52-Week Range:

$10.25

$19.09

Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile

Name

Avadel Pharmaceuticals Plc

Sector

Healthcare (1181)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

636-449-1830

Address

BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN

Employee

154

Twitter

@AvadelPharma

Next Earnings Date

2024-11-06

Latest SEC Filings

AVDL's Discussions on Twitter

Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-12-24	Initiated	Rodman & Renshaw	Buy
Mar-05-24	Reiterated	H.C. Wainwright	Buy
Mar-05-24	Reiterated	Needham	Buy
Mar-05-24	Reiterated	Oppenheimer	Outperform
Feb-06-24	Initiated	UBS	Buy
Nov-30-22	Upgrade	Jefferies	Hold → Buy
Aug-10-22	Downgrade	Jefferies	Buy → Hold
Jul-28-22	Resumed	Craig Hallum	Buy
May-26-22	Downgrade	Stifel	Buy → Hold
Sep-23-21	Initiated	Needham	Buy
Jul-31-20	Initiated	Oppenheimer	Outperform
Jul-21-20	Initiated	SVB Leerink	Outperform
Jun-30-20	Initiated	H.C. Wainwright	Buy
Apr-03-20	Initiated	Jefferies	Buy
Mar-12-20	Initiated	Stifel	Buy
Feb-26-20	Initiated	Piper Sandler	Overweight
Jan-30-20	Initiated	Craig Hallum	Buy
Jun-14-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Feb-08-19	Downgrade	Ladenburg Thalmann	Buy → Neutral

View All

Avadel Pharmaceuticals Plc Stock (AVDL) Latest News

Nov 04, 2024

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 - The Manila Times

Nov 04, 2024

Avadel Pharmaceuticals (NASDAQ:AVDL) Earns “Buy” Rating from Needham & Company LLC - Defense World

Nov 04, 2024

Oppenheimer Forecasts Strong Price Appreciation for Avadel Pharmaceuticals (NASDAQ:AVDL) Stock - Defense World

Nov 04, 2024

Avadel Pharmaceuticals’ (AVDL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 04, 2024

Nov 01, 2024

Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz - Sleep Review

Nov 01, 2024

US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Yahoo Finance

Nov 01, 2024

Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term - Yahoo Finance

Nov 01, 2024

Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL) - Defense World

Nov 01, 2024

Oct 31, 2024

Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ By Investing.com - Investing.com South Africa

Oct 31, 2024

Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap UpStill a Buy? - MarketBeat

Oct 31, 2024

Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ - Investing.com

Oct 31, 2024

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation - Marketscreener.com

Oct 31, 2024

Shares Rally Up For Avadel (AVDL) As Court Rules Favorably - Stocks Telegraph

Oct 31, 2024

Needham & Company LLC Reiterates "Buy" Rating for Avadel Pharmaceuticals (NASDAQ:AVDL) - MarketBeat

Oct 31, 2024

Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma - MSN

Oct 31, 2024

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - The Manila Times

Oct 31, 2024

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Bought by Iridian Asset Management LLC CT - MarketBeat

Oct 31, 2024

Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances - StockTitan

Oct 24, 2024

Oct 23, 2024

Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 23, 2024

Oct 21, 2024

Avadel Pharmaceuticals' (AVDL) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 21, 2024

H.C. Wainwright maintains Buy rating on Avadel shares as FDA approves LUMRYZ for pediatrics - Investing.com UK

Oct 21, 2024

Needham & Company LLC Reaffirms Buy Rating for Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World

Oct 21, 2024

Oct 20, 2024

Claro Advisors LLC Has $644,000 Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - MarketBeat

Oct 20, 2024

Oct 18, 2024

Avadel wins FDA approval for narcolepsy drug Lumryz in children - Pharmaceutical Technology

Oct 18, 2024

Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz - Benzinga

Oct 18, 2024

Avadel Pharmaceuticals' (AVDL) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Oct 18, 2024

Oct 17, 2024

FDA Expands Approval of LUMRYZ for Pediatric Narcolepsy - Sleep Review

Oct 17, 2024

FDA approves Avadel's narcolepsy drug for pediatric use - Investing.com

Oct 17, 2024